The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
To create leading company developing medicines targeting metalloenzymes
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Subscribe To Our Newsletter & Stay Updated
